New treatment plan for high-risk aggressive lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests a treatment sequence for people with high-risk diffuse large B-cell lymphoma (DLBCL) that includes loncastuximab plus rituximab, then DA-EPOCH-R. It aims to improve responses in patients whose lymphoma has specific high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have untreated DLBCL with specific high-risk test results (including MYC and BCL2 or rearrangements).
- Your scans (CT or PET/CT) show measurable lymphoma with at least one tumor site 1.5 cm or larger.
- You are age 18 or older, and your general health is good enough (ECOG 0–2).
- Blood counts and organ function meet safety minimums (enough white cells, neutrophils, platelets, hemoglobin, and bilirubin/liver enzyme levels).
- You can use reliable birth control if you could become pregnant (or your partner can), and you are not breastfeeding.
- You do not have certain recent treatments or major medical problems (for example, no uncontrolled CNS lymphoma or major active infections).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This trial tests a new sequence of two chemotherapy regimens (RLC followed by CR-CHOP) for elderly patients with a fast-growing DLBCL called double expressor lymphoma. The goal is to see if this approach is safe and effective for people who may not tolerate standard treatments.
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
This study tests whether adding epcoritamab, a new immunotherapy drug, to standard chemotherapy (R-CHOP) can help patients with aggressive B-cell lymphomas. The goal is to see if this combination works better than chemotherapy alone.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
Hear when a new Double Expressor Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.